Europe Metabolomics Market

Europe Metabolomics Market Size (2023 to 2028)

As per our report, the Europe Metabolomics Market size has been calculated at USD 663.72 Million in 2023. It is estimated to grow at a CAGR of 18.4% between 2023 to 2028 and worth USD 1728.77 Million by 2028.

Metabolomics is the considerable scale research of minute molecules, usually known as metabolites, inside cells, tissues, or living beings. Aggregately, these tiny particles and their associations inside an organic framework are known as the metabolome. Therefore, metabolomics characterizes the microscopic phenotype. Metabolomics is a skilled approach since metabolites and their concentration, not like other "omics" measures, directly reflect the hidden biochemical movement and state of cells. The European Metabolomics market is emerging at a rapid speed.

Govt. financing and private funding are also reassuring the growth of this market. Metabolomics is gradually sought after as they help in shrinking the hole between genotype and phenotype by offering a whole perspective of the cell working. Stable, innovative advances and looks into will guarantee a proceeded with the development of this market and decrease these restrictions' effect in the future. Nonetheless, the unexplored markets in evolving countries will spur new progress open doors for market players.

This research report on the Europe Metabolomics Market has been segmented and sub-segmented into the following categories:

By Product: 

• GC
• Bioinformatics
• Mass Spectrometry
• HPLC
• UPLC
• NMRS
• Surface-based mass analysis

By Indication: 

• Oncology
• Cardiology
• Inborn Error

By Application: 

• Nutrigenomics
• Toxicology
• Biomarker 
• Drug Discovery

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The Biomarker Discovery segment had the largest share in 2016 in the global metabolomics market based on application. Efficiency and reliability have been cited as the reason for the growth of biomarkers. However, a collaboration between biotechnology and pharmaceutical companies, the personalized medical segment is expected to have the highest CAGR.

Based on the region, Europe had the least CAGR during the forecast period. The reasons for the same might be government policies.

Notable companies leading the Europe Metabolomics Market profiled in the report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.).